

Original Research

Repetitive Skin Focused Disorders May Express a Functional Connectome

Colleen M. Reisz, MD*

Assistant Clinical Professor of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA

*Corresponding author

Colleen M. Reisz, MD

Assistant Clinical Professor of Medicine, University of Missouri-Kansas City, Kansas City, Missouri, USA; Tel. 816-454-0666; E-mail: cmrderm@aol.com

Article Information

Received: December 20th, 2018; **Revised:** January 8th, 2019; **Accepted:** January 8th, 2019; **Published:** January 19th, 2019

Cite this article

Reisz CM. Repetitive skin focused disorders may express a functional connectome. *Soc Behav Res Pract Open J.* 2019; 4(1): 1-7. doi: [10.17140/SBRPOJ-4-114](https://doi.org/10.17140/SBRPOJ-4-114)

ABSTRACT

Background

Repetitive skin focused behaviors, such as nail biting, hair pulling, cutting, and others may involve brain regions that participate in visual and tactile awareness, contextual learning and anxiety.

Methods

Gender and age of onset were collected on 78 patients with a repetitive skin focused disorder from a general dermatology clinic between 2014-2018. The disorders included onychophagia (nail biting), trichotillomania (hair pulling), cutting, pathologic skin picking, acne excoriée (popping pimples) and delusions of infestations.

Results

Sixty/Seventy-eight, (77%) of the patients were female. Onychophagia, trichotillomania, and cutting emerged during key developmental milestones, such as adrenarche and pubarche. The 17 patients with delusions of infestations were middle-aged, between 52-66. Five/Seventy-eight (6%) attempted suicide, all female, three successfully.

Conclusions

Repetitive skin focused behaviors may reflect potentiation in neural circuits that participate in contextual processing, tactile and visual awareness. Trends emerged in gender predominance and age of onset. These disorders may have clinical utility in two key areas, emotional regulation in teenagers and drug toxicity in adults.

Trial Registration

UMKC IRB 16-464.

Keywords

Onychophagia; Trichotillomania; Delusions of infestations; Human connectome project; Locus coeruleus.

INTRODUCTION

Advances in neuroscience are occurring alongside wildly expanding clinical needs in depression and suicide, delirium and dementia.¹⁻⁴ Individuals contemplating suicide or harm to others are interfacing with health care systems that are either not recognizing those at risk or are not putting the riskiest patients in front of the clinicians with the greatest diagnostic acumen.⁵⁻⁷ Clinicians rely on what the patient says, how they say it, and often include performance and cognitive measures to assign a diagnosis.⁸⁻⁹ Many patients seen for routine medical exams have unrecognized needs for mental health care.

Altered patterns of self-grooming have been used to identify anxiety and obsessive-compulsive disorders (OCD) in animals.¹⁰⁻¹² Repetitive grooming behaviors are also seen in humans. Onychophagia (nail biting), trichotillomania (hair pulling), cutting and picking, repetitive piercing and tattooing, excessive use of cosmetic procedures, are common observations in clinical practice (Figures 1 and 2).¹³⁻¹⁷ Repeated behaviors that involve the skin, especially those that leave marks or are accompanied by specimens, can be seen, graded and noted in the chart. In laboratory settings, neuroscientists have created maps of brain function and circuitry in task and non-task related situations.¹⁸ Each hemisphere has been parcellated into regions defined by changes in

Figure 1. Onychophagia in a Middle Aged Adult Male



Figure 2. Scars from Cutting on the Ventral Forearms



Figure 3. Diagram of Projections to and from the Locus Coeruleus

AFFERENTS OF LOCUS COERULEUS





Figure 4. Diagram of Projections to and from the Locus Coeruleus

EFFERENTS OF LOCUS COERULEUS



architecture, topography, connections, and function.¹⁹⁻²⁰ The study of fear conditioning has identified the brain regions that operate together to acquire memory and project that input to the amygdala and hippocampus for emotional processing.²¹⁻²⁴ The olfactory bulb functions as a relay station for environmental clues to admix with new neurons migrating from the dentate gyrus.²⁵⁻²⁹ The locus coeruleus (LC), located in the pons, is a key hub in the governance of the noradrenergic system, and processes the physiologic changes clinicians see in anxious and alert situations (Figures 3 and 4).³⁰⁻³⁴ Variation in heart rate and breathing, freeze and startle responses, pupil dilation, and blinking, sweat conductance in the palms, reflect the contribution of noradrenergic feedback on neural pathways.³⁴⁻³⁹

The LC receives input from over 100 regions in the nerv-

ous system and then projects to targets that activate the physiologic responses to the challenge.³⁰ The repetitive nature of the skin focused responses may accompany changes in the environment, phasic changes in hormones, fear, and memory-related tasks, and drug alteration in neurotransmitters. The development of fully characterized phenotypes around repetitive skin focused disorders may trigger clinical decision support in several areas; emotional well being in puberty, adults at risk for off-target drug effects and individuals with suicidal ideation.

METHODS

The patient data was obtained out of a general dermatology clinic between 2014 and 2018. The study was approved by the Institutional Review Board of the University of Missouri-Kansas City and in-


formed consent was obtained from all participants included in the study. The patients presenting with trichotillomania and delusions of infestations used hair loss and sensations of animate material in the skin as their reason for a visit. The rest of the patients were enrolled after a repetitive skin focused behavior was observed during a routine clinical examination. When these findings were recognized, the nature of the study was presented to the patient and informed consent was obtained. The patients were informed that their data would be de-identified and would include age, gender, and age of onset. In addition, all patients with delusions of infestation underwent detailed histories of medical events, medication adjustments and the use of supplements. All material (specimen sign) brought in by the patient was examined under the microscope to document lack of an infestation. Sample: 78 patients were identified with a repetitive skin focused behavior. 60/78 (77%) were female. Onychophagia (n=19, 12/19 female), had the earliest presentation, between ages 3-8. Trichotillomania (n=20, 17/20 female) and cutting (n=9, 6/9 female) appeared between ages 12-14. Acne excoriée and picking (n=13, 12/13 female) emerged at two different points, ages 12-15 and 30-54. Delusions of infestations (n=17, 13/17 female) presented between ages 52-63.

RESULTS

Repetitive skin focused disorders are seen more commonly in women. All of the disorders, with the exception of delusions of infestations, had origins close to a developmental milestone (Figure 5). Eight/Seventeen (47%) of the patients presenting with delusions of infestations believed the infestation could be traced to a

single event, such as exposure to mold, breaking glass or travel to a foreign country, suggesting overlap with fear conditioning. Within this group were trends towards polypharmacy and excessive use of

Figure 5. Repetitive Skin Focused Disorders According to Age of Onset. Delusions of Parasitosis and Morgellons Disease Now Recognized as the Same Process, Delusions of Infestations



supplements. A change in drug type or dose occurred around the time the delusion started in 9/17 (53%). Three/Seventeen (18%) had the same drug change, lisdexafetamine to dexamphetamine/amphetamine. Other drug changes included continual adjustments in intrathecal bupivacaine and morphine; Simultaneous drug changes from amlodipine to losartan and fluoxetine to citalopram in one woman. Five/Seventeen (29%) patients were on opioids. Two/Seventeen disclosed illicit use of methamphetamine and hydrocodone. Seven/Seventeen (41%) were avid consumers of nutraceuticals (Table 1).

Table 1. Pharmaceutical and Supplement Data on 17 Patients with Delusions of Infestations

Age of Onset	Gender	Associated Findings
52	Female	Ingestion of "all green super food" supplement product line
56	Female	polypharmacy (defined as 5 or greater drugs)
56	Female	Symptoms began after taking DHEA supplementation
63	Female	Polypharmacy in addition to varying doses in intrathecal pain pump
60	Female	Alcohol abuse and multiple anxiolytics
60	Female	Cutting her hand after dropping a glass plate. At time of injury, statin, SSRI and ARB, which continue
57	Male	Symptoms began after cutting from lisdexafetamine to dexamphetamine
63	Female	Solaray vitamin supplementation
45	Male	Work related fiberglass exposure near time of job loss. Ongoing methamphetamine and cocaine exposure
45	Female	Clonazepam, lisdexamefatmine to dexamphetamine
44	Female	Sertraline, naltrexone. Symptoms began after sertraline doubled in dose.
54	Female	Testosterone injections at 48, bioidentical troches purchased off the internet, 8 additional supplements
49	Female	Effexor, metoprolol, positive urine drug screen for oxycodone
71	Female	Duloxetine, lisinopril, dexamphetamine, simvastatin, supplements. Started after coma after surgery complications at age 67
68	Female	Simvastatin, amlodipine: sensation started after change from lisinopril to amlodipine/olmesartan and did not resolve with cessation of olmesartan
45	Male	Specimen sign, dexamphetamine
53	Female	Specimen sign, armodafanil, esomeprazole, dexamphetamine, nucynta, apple cider vinegar, fish oil

Five/Seventy-eight (6%) patients attempted suicide, all female, three successfully. The successful suicides were seen in women with extreme presentations of a repetitive skin focused disorder. These included near total scalp trichotillomania, the presentation of elaborate microscopic images of normal skin and hair clippings, and deep mutilating scars on the wrists. 4/5 of this group described multiple suicide attempts.

DISCUSSION

Clinicians need additional tools to assess risk for self-harm or the emergence of thoughts to hurt others. Many psychiatric and neurologic diseases proceed over a temporal continuum, an initial complaint or observable feature, viewed in isolation, may not register as a critical feature until additional and more severe expressions unmask the true potential of the problem. In a study of 571 suicides, 41% had sought health care within 4-weeks of their death, although far fewer disclosed their intent during the visit.⁴⁰⁻⁴² There is a similar problem with mass shooters. Often those closest to them have no idea of their plans.⁴³

There may be aspects of the physical exam that would provide additional information to the provider on the emotional regulation of the patient, no matter the reason for a visit. The age of onset, gender, proximity to a developmental milestone or a medication change, could be key diagnostic features in a machine learning paradigm.⁴⁴ Seventy-seven percent of the patients in this series were female, suggesting that there may be gender differences in brain regions involved with emotion and perception (Table 2).⁴⁵⁻⁵⁰

Table 2. Age and Gender of Patients with Repetitive Skin Focused Disorders

Condition	N	Median Age of Onset	Onset Range	M:F	M:F%
Onychophagia	19	7	3-24	7:12	37:63
Cutting	9	15	14-18	3:6	33:67
Trichotillomania	20	15	6-54	3:17	15:85
Picking/acne excoriée	13	26	12-15 and 30-54	1:12	8:92
Delusions of Infestations	17	59	52-63	4:13	24:76

The effect of oral contraceptives and menstrual cycle phase on fear, memory, and anxiety remain largely unknown.⁵¹⁻⁵² Women approach medical care differently, being open to taking prescriptions while also showing interest in natural approaches that include supplements and self-directed care.⁵³⁻⁵⁴

A review of classic drug-induced neurotoxic syndromes reveal specific vulnerabilities in the basal ganglia, the autonomic nervous system, and areas related to sleep, anxiety and thought.⁵⁵⁻⁶⁰ The enzymatic oxidation of cholesterol to bile provides key metabolic functions, such as drug metabolism, the absorption of dietary lipids and protection of the endocrine system. Drug metabolism uses the same pathway as cholesterol catabolism. These pathways are inducible and can be compromised by age, illness, and co-ingestion with other medications.⁶¹ The cholesterol-bile salt pathway

is a frequent target of the pharmaceutical industry for diabetes, metabolic and cardiovascular disease.⁶² Two commonly prescribed drug classes, HMG-CoA receptor antagonists (statins) and proton pump inhibitors (PPI's), were introduced in 1987 and 1990, respectively. Omeprazole, the first drug in this class to be introduced, inhibits the main efflux transporter in many organs, including the blood-brain barrier, permeability glycoprotein-1 (Pgp-1).⁶³ These two drug classes, statins and PPI's, are frequently seen in combination and impact the bile salt pathway and the receptors that govern drug clearance in ways that may not be predictable or recognized as an off target drug effect. Dopamine agonists, prescribed for Parkinson's disease and restless leg syndrome, can disrupt reward systems related to sex and gambling, although this is rarely brought up in the clinic.⁶⁴ Specialty visits usually focus on a specific outcome, and dose adjustments are made to performance measures of that outcome. Statins are adjusted for cardiovascular risk, Parkinson's medications titrated for tremor, additional adjustments are made for gastric reflux, bladder irritability, pain, and so forth, neglecting the balance of effect on other issues that may be of real importance to the patient.⁶⁵ Patients presenting with early drug-induced neurotoxicity syndromes tend to be exposed to a wide variety of medical practitioners including primary care providers, dermatologists, dentists, gastroenterologists, otolaryngologists, neurologists, psychiatrists. The common cause of injury (drug toxicity) is missed because each specialty is focusing on its specific dysfunction rather than the overall pattern.

Research on neural function has little uniformity and diagnostic categorizations do not scale across providers and researchers.⁶⁶⁻⁶⁸ Our most basic clinical needs, the need to identify those at risk for self-harm and harm to others, are not being met. Repetitive skin focused disorders may reflect potentiated and possibly toxic communication between the thalamus, amygdala, locus coeruleus, insula, and hippocampus. The development of fully characterized phenotypes around repetitive skin focused disorders may provide a 'risk signature' that would scale across provider types.

CONCLUSIONS

There are missed opportunities in health care for individuals with mental health issues. Clinicians observe the manifestations of repetitive skin focused behaviors every day but may not know what to call it, how it should be factored into complex clinical presentations or whether the reason for a visit should be shifted to include emotional well-being. The development of fully characterized phenotypes around repetitive skin focused disorders may trigger clinical decision support in three key areas; mental health issues that emerge at puberty, adults at risk for polypharmacy and individuals with suicidal ideation.

CONFLICTS OF INTEREST

There was no funding obtained and the author has no financial conflicts of interest.

REFERENCES

- Patel V, Flisher A, Hetrick S, McGorry P. Mental health of young people: A global public-health challenge. *Lancet*. 2007; 369(9569): 1302-1313. doi: [10.1016/S0140-6736\(07\)60368-7](https://doi.org/10.1016/S0140-6736(07)60368-7)
- Cassidy SA, Bradley L, Bowen E, Wigham S, Rodgers J. Measurement properties of tools used to assess suicidality in autistic and general population adults: A systematic review. *Clin Psychol Rev*. 2018; 62: 56-70. doi: [10.1016/j.cpr.2018.05.002](https://doi.org/10.1016/j.cpr.2018.05.002)
- Horowitz LM, Wang PS, Koocher GP, et al. Detecting suicide risk in a pediatric emergency department: Development of a brief screening tool. *Pediatrics*. 2001; 107(5): 1133-1137.
- Cappelli M, Gray C, Zemek R, et al. The HEADS-ED: A rapid mental health screening tool for pediatric patients in the emergency department. *Pediatrics*. 2012; 130(2): e321-e327. doi: [10.1542/peds.2011-3798](https://doi.org/10.1542/peds.2011-3798)
- Ballard ED, Cwik M, Van Eck K, et al. Identification of at-risk youth by suicide screening in a pediatric emergency department. *Prev Sci*. 2017; 18(2): 174-182. doi: [10.1007/s11121-016-0717-5](https://doi.org/10.1007/s11121-016-0717-5)
- Zbozinek T, Rose R, Wolitzky-Taylor K. Diagnostic overlap of generalized anxiety disorder and major depressive disorder in a primary care sample. *Depress Anxiety*. 2012; 29(12): 1065-1071. doi: [10.1002/da.22026](https://doi.org/10.1002/da.22026)
- Masten AS. *Adolescent Psychopathology and the Developing Brain*. Integrating Brain and Prevention Science. Romer D, Walker EF (Eds). New York, USA: Oxford University Press. 2007.
- Gershon RC, Cella D, Fox NA, Havlik RJ, Hendrie HC, Wagster MV. Assessment of neurological and behavioural function: the NIH Toolbox. *Lancet Neurol*. 2010; 9(2): 138-139. doi: [10.1016/S1474-4422\(09\)70335-7](https://doi.org/10.1016/S1474-4422(09)70335-7)
- Sareen J, Cox B, Affi T, et al. Anxiety disorders and risk for suicidal ideation and suicide attempts: A population-based longitudinal study of adults. *Arch Gen Psychiatry*. 2005; 62(11): 1249-1257. doi: [10.1001/archpsyc.62.11.1249](https://doi.org/10.1001/archpsyc.62.11.1249)
- Singh H, Graber ML. Improving diagnosis in health care-the next imperative for patient safety. *N Engl J Med*. 2015; 373(26): 2493-2495. doi: [10.1056/NEJMp1512241](https://doi.org/10.1056/NEJMp1512241)
- Lahti A, Harju A, Hakko H, Riala K, Räsänen P. Suicide in children and young adolescents: A 25-year database on suicides from Northern Finland. *J Psychiatr Res*. 2014; 58: 123-128. doi: [10.1016/j.jpsychires.2014.07.020](https://doi.org/10.1016/j.jpsychires.2014.07.020)
- Kim H, Lim C, Kaang B. Neuronal mechanisms and circuits underlying repetitive behaviors in mouse models of autism spectrum disorder. *Behav Brain Funct*. 2016; 12(1): 3. doi: [10.1186/s12993-016-0087-y](https://doi.org/10.1186/s12993-016-0087-y)
- Zike I, Xu T, Hong N, Veenstra-VanderWeele J. Rodent models of obsessive-compulsive disorder: Evaluating validity to interpret emerging neurobiology. *Neuroscience*. 2017; 345: 256-273. doi: [10.1016/j.neuroscience.2016.09.012](https://doi.org/10.1016/j.neuroscience.2016.09.012)
- Ricketts EJ, Snorrason Í, Kircanski K, et al. A latent profile analysis of age of onset in pathological skin picking. *Compr Psychiatry*. 2018; 87: 46-52. doi: [10.1016/j.comppsy.2018.08.011](https://doi.org/10.1016/j.comppsy.2018.08.011)
- Chamberlain SR, Odlaug BL, Boulougouris V, Fineberg NA, Grant JE. Trichotillomania: Neurobiology and treatment. *Neurosci Biobehav Rev*. 2009; 33(6): 831-842. doi: [10.1016/j.neubiorev.2009.02.002](https://doi.org/10.1016/j.neubiorev.2009.02.002)
- Zetterqvist M. The DSM-5 diagnosis of nonsuicidal self-injury disorder: A review of the empirical literature. *Child Adolesc Psychiatry Ment Health*. 2015; 9: 31. doi: [10.1186/s13034-015-0062-7](https://doi.org/10.1186/s13034-015-0062-7)
- Flessner C, Knopik V, McGeary J. Hair pulling disorder (trichotillomania): Genes, neurobiology, and a model for understanding impulsivity and compulsivity. *Psychiatry Res*. 2012; 199(3): 151-158. doi: [10.1016/j.psychres.2012.03.039](https://doi.org/10.1016/j.psychres.2012.03.039)
- Fox MD. Mapping symptoms to brain networks with the Human Connectome. *N Engl J Med*. 2018; 379: 2237-2245. doi: [10.1056/NEJMr1706158](https://doi.org/10.1056/NEJMr1706158)
- Glasser MF, Coalson TS, Robinson EC, et al. A multi-modal parcellation of human cerebral cortex. *Nature*. 2016 Aug 11; 536(7615): 171-178. doi: [10.1038/nature18933](https://doi.org/10.1038/nature18933)
- Gardner D, Akil H, Ascoli G, et al. The neuroscience information framework: A data and knowledge environment for neuroscience. *Neuroinformatics*. 2008; 6(3): 149-160. doi: [10.1007/s12021-008-9024-z](https://doi.org/10.1007/s12021-008-9024-z)
- Lijie Wang, Jinping Xu, Chao Wang, Jiaojian Wang. Whole brain functional connectivity pattern homogeneity mapping. *Front Hum Neurosci*. 2018; 12: 164. doi: [10.3389/fnhum.2018.00164](https://doi.org/10.3389/fnhum.2018.00164)
- LeDoux JE. Emotion circuits in the brain. *Annu Rev Neurosci*. 2000; 23: 155-184. doi: [10.1146/annurev.neuro.23.1.155](https://doi.org/10.1146/annurev.neuro.23.1.155)
- Romer D, Reyna VF, Satterthwaite TD. Beyond stereotypes of adolescent risk taking: Placing the adolescent brain in developmental context. *Dev Cogn Neurosci*. 2017; 27: 19-34. doi: [10.1016/j.dcn.2017.07.007](https://doi.org/10.1016/j.dcn.2017.07.007)
- Consortium B, Anttila V, Bulik-Sullivan B, et al. Analysis of shared heritability in common disorders of the brain. *Science*. 2018; 360(6395). doi: [10.1126/science.aap8757](https://doi.org/10.1126/science.aap8757)
- Frey U, Morris RG. Synaptic tagging and long-term potentia-

tion. *Nature*. 1997; 385: 533-538. doi: [10.1038/385533a0](https://doi.org/10.1038/385533a0)

26. Douglas RM, Goddard GV. Long-term potentiation of the perforant path-granule cell synapse in the rat hippocampus. *Brain Res*. 1975; 86(2): 205-215.

27. Guo-li Ming, Hongjun Song. Adult neurogenesis in the mammalian brain: Significant answers and significant questions. *Neuron*. 2011; 70(4): 687-702. doi: [10.1016/j.neuron.2011.05.001](https://doi.org/10.1016/j.neuron.2011.05.001)

28. Kay LM, Beshel J, Brea J, Martin C, Rojas-Libano D, Kopell N. Olfactory oscillations: The what, how and what for. *Trends Neurosci*. 2009; 32(4): 207-214. doi: [10.1016/j.tins.2008.11.008](https://doi.org/10.1016/j.tins.2008.11.008)

29. Malvaut S, Saghatelian A. The role of adult-born neurons in the constantly changing olfactory bulb network. *Neural Plasticity*. 2016; 1614329. doi: [10.1155/2016/1614329](https://doi.org/10.1155/2016/1614329)

30. Fukunaga I, Berning M, Kollo M, Schmaltz A, Schaefer AJ. Two distinct channels of olfactory bulb output. *Neuron*. 2012; 75(2): 320-329. doi: [10.1016/j.neuron.2012.05.017](https://doi.org/10.1016/j.neuron.2012.05.017)

31. Schwarz LA, Luo L. Organization of the locus coeruleus-noradrenergic system. *Curr. Biol*. 2015; 25: R1051-R1056. doi: [10.1016/j.cub.2015.09.039](https://doi.org/10.1016/j.cub.2015.09.039)

32. Carlson NR, Birkett MA. *Physiology of Behavior*. New Jersey, USA: Pearson Education, Inc. 2017; 559-576.

33. Vietl D. Interoception. *Biological Psychology*. 1996; 42(1-2): 1-27. doi: [10.1016/0301-0511\(95\)05144-9](https://doi.org/10.1016/0301-0511(95)05144-9)

34. Dalton KM, Nacewicz BM, Johnstone T, et al. Gaze fixation and the neural circuitry of face processing in autism. *Nat Neurosci*. 2005; 8(4): 519-526. doi: [10.1038/nm1421](https://doi.org/10.1038/nm1421)

35. Gilzenrat MS, Nieuwenhuis S, Jepma M, Cohen JD. Pupil diameter tracks changes in control state predicted by the adaptive gain theory of locus coeruleus function. *Cogn Affect Behav Neurosci*. 2010; 10(2): 252-269. doi: [10.3758/CABN.10.2.252](https://doi.org/10.3758/CABN.10.2.252)

36. Thorell LH, Wolfersdorf M, Straub R, et al. Electrodermal hyporeactivity as a trait marker for suicidal propensity in uni- and bipolar depression. *J Psychiatr Res*. 2013; 47(12): 1925-1931. doi: [10.1016/j.jpsychires.2013.08.017](https://doi.org/10.1016/j.jpsychires.2013.08.017)

37. Sarchiapone M, Gramaglia C, Iossue, et al. The association between electrodermal activity (EDA), depression and suicidal behaviour: A systematic review and narrative synthesis. *BMC Psychiatry*. 2018; 18(1): 22. doi: [10.1186/s12888-017-1551-4](https://doi.org/10.1186/s12888-017-1551-4)

38. Moretta T, Buodo G. Autonomic stress reactivity and craving in individuals with problematic internet use. *PLoS One*. 2018; 13(1): e0190951. doi: [10.1371/journal.pone.0190951](https://doi.org/10.1371/journal.pone.0190951)

39. Wang P, Gao Y, Isen J, Tuvblad C, Raine A, Baker LA. Genetic covariance between psychopathic traits and anticipatory skin conductance responses to threat: Evidence for a potential endophenotype. *Dev Psychopathol*. 2015; 27(4 Pt 1): 1313-1322. doi: [10.1017/S0954579414001424](https://doi.org/10.1017/S0954579414001424)

40. Sudol K, Mann JJ. Biomarkers of suicide attempt behavior: Towards a biological model of risk. *Curr Psychiatry Rep*. 2017; 19(6): 31. doi: [10.1007/s11920-017-0781-y](https://doi.org/10.1007/s11920-017-0781-y)

41. Eippert F, Veit R, Weiskopf N, Erb M, Birbaumer N, Anders S. Regulation of emotional responses elicited by threat-related stimuli. *Hum Brain Mapp*. 2007; 28(5): 409-423. doi: [10.1002/hbm.20291](https://doi.org/10.1002/hbm.20291)

42. Suominen K, Isometsä E, Marttunen M, Ostamo A, Lönnqvist J. Health care contacts before and after attempted suicide among adolescent and young adult versus older suicide attempters. *Psychol Med*. 2004; 34(2): 313-321

43. Klebold S, Soloman A. *A Mother's Reckoning: Living in the Aftermath of Tragedy*. New York, USA: Broadway Books. 2016.

44. Combi C, Keravnou-Papailiou E, Shahar Y. *Temporal Information Systems in Medicine*. New York, USA: Springer. 2010; 249-297.

45. Cahill L. Why sex matters for neuroscience. *Nat Rev Neurosci*. 2006; 7(6): 477-484. doi: [10.1038/nrn1909](https://doi.org/10.1038/nrn1909)

46. Barth C, Villringer A, Sacher J. Sex hormones affect neurotransmitters and shape the adult female brain during hormonal transition periods. *Front Neurosci*. 2015; 9:37. doi: [10.3389/fnins.2015.00037](https://doi.org/10.3389/fnins.2015.00037)

47. Nielsen SE, Ertman N, Lakhani YS, Cahill L. Hormonal contraception usage is associated with altered memory for an emotional story. *Neurobiology of learning and memory*. 2011; 96(2): 378-384. doi: [10.1016/j.nlm.2011.06.013](https://doi.org/10.1016/j.nlm.2011.06.013)

48. van Wingen GA, van Broekhoven F, Verkes RJ, et al. Progesterone selectively increases amygdala reactivity in women. *Mol Psychiatry*. 2008; 13(3): 325-333. doi: [10.1038/sj.mp.4002030](https://doi.org/10.1038/sj.mp.4002030)

49. Ingallhalikar M, Smith A, Parker D, et al. Sex differences in the structural connectome of the human brain. *Proc Natl Acad Sci U S A*. 2014; 111(2): 823-828. doi: [10.1073/pnas.1316909110](https://doi.org/10.1073/pnas.1316909110)

50. Bixo M, Johansson M, Timby E, Michalski L, Bäckström T. Effects of GABA active steroids in the female brain with a focus on the premenstrual dysphoric disorder. *J Neuroendocrinol*. 2018; 30(2). doi: [10.1111/jne.12553](https://doi.org/10.1111/jne.12553)

51. Karpinski M, Mattina G, Steiner M. Effect of gonadal hormones on neurotransmitters implicated in the pathophysiology of obsessive-compulsive disorder: A critical review. *Neuroendocrinology*. 2017; 105(1): 1-16. doi: [10.1159/000453664](https://doi.org/10.1159/000453664)

52. Altemus M, Sarvaiya, N, Neill Epperson C. Sex differences in anxiety and depression clinical perspectives. *Front Neuroendocrinol.* 2014; 35(3): 320-330. doi: [10.1016/j.yfrne.2014.05.004](https://doi.org/10.1016/j.yfrne.2014.05.004)
53. Soldin OP, Mattison DR. Sex differences in pharmacokinetics and pharmacodynamics. *Clin Pharmacokinet.* 2009; 48(3): 143-157. doi: [10.2165/00003088-200948030-00001](https://doi.org/10.2165/00003088-200948030-00001)
54. Miller MA. Gender-Based Differences in the toxicity of pharmaceuticals—The food and drug administration's perspective. *Int J Toxicol.* 200; 20(3): 149-152. doi: [10.1080/109158101317097728](https://doi.org/10.1080/109158101317097728)
55. Reisz C. Recognizing off target drug effects at the gut and brain. *Neurosci Commun.* 2016; e1315. doi: [10.14800/nc.1315](https://doi.org/10.14800/nc.1315)
56. Ropper AH, Brown RH. Chapter 4. Abnormalities of Movement and Posture Caused by Disease of the Basal Ganglia. *Adam and Victor's Principles of Neurology.* New York, USA: McGraw Hill. 2005; 55-70.
57. Ropper AH, Brown RH. Chapter 43. Disorders of the Nervous System due to Drugs, Toxins and other Chemical Agents. *Adam and Victor's Principles of Neurology.* New York, USA: McGraw Hill. 2005; 1016-1045.
58. Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention. *JAMA.* 1995; 274(1): 29-34.
59. Weingart SN, Gandhi TK, Seger AC, et al. Patient-reported medication symptoms in primary care. *Arch Intern Med.* 2005; 165(2): 234-240. doi: [10.1001/archinte.165.2.234](https://doi.org/10.1001/archinte.165.2.234)
60. Qato DM, Ozenberger K, Olfson M. Prevalence of prescription medications with depression as a potential adverse effect among adults in the United States. *JAMA.* 2018; 319(22): 2289-2298. doi: [10.1001/jama.2018.6741](https://doi.org/10.1001/jama.2018.6741)
61. Ioannidis JP, Lau J. Completeness of safety reporting in randomized trials: An evaluation of 7 medical areas. *JAMA.* 2001; 285(4): 437-443.
62. de Aguiar Vallim TQ, Tarling EJ, Edwards PA. Pleiotropic roles of bile acids in metabolism. *Cell Metab.* 2013; 17(5): 657-669. doi: [10.1016/j.cmet.2013.03.013](https://doi.org/10.1016/j.cmet.2013.03.013)
63. Cordon-Cardo C, O'Brien JP, Boccia J, Casals D, Bertino JR, Melamed MR. Expression of the multidrug resistance gene product (P-glycoprotein) in human normal and tumor tissues. *J Histochem Cytochem.* 1990; 38(9): 1277-1287. doi: [10.1177/38.9.1974900](https://doi.org/10.1177/38.9.1974900)
64. Grall-Bronnec M, Victorri-Vigneau C, Donnio Y, et al. Dopamine agonists and impulse control disorders: A complex association. *Drug Saf.* 2018; 41(1): 19-75. doi: [10.1007/s40264-017-0590-6](https://doi.org/10.1007/s40264-017-0590-6)
65. Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. *BMC Geriatr.* 2017; 17(1): 230. doi: [10.1186/s12877-017-0621-2](https://doi.org/10.1186/s12877-017-0621-2)
66. Insel T, Cuthbert B, Garvey M, et al. Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. *Am J Psychiatry.* 2010; 167(7): 748-751. doi: [10.1176/appi.ajp.2010.09091379](https://doi.org/10.1176/appi.ajp.2010.09091379)
67. Lilienfeld S, Treadway M. Clashing diagnostic approaches: DSM-ICD Versus RDoC. *Annu Rev Clin Psychol.* 2016; 12: 435-463. doi: [10.1146/annurev-clinpsy-021815-093122](https://doi.org/10.1146/annurev-clinpsy-021815-093122)
68. Szabadi E. Functional neuroanatomy of the central noradrenergic system. *J Psychopharmacol.* 2013; 27(8): 659-693. doi: [10.1177/0269881113490326](https://doi.org/10.1177/0269881113490326)